Advertisement

CardioVascular and Interventional Radiology

, Volume 42, Issue 2, pp 260–267 | Cite as

Visibility of Hypovascularized Liver Tumors during Intra-Arterial Therapy Using Split-Bolus Single-Phase Cone Beam CT

  • Martin JonczykEmail author
  • Federico Collettini
  • Dirk Schnapauff
  • Dominik Geisel
  • Georg Böning
  • Willie M. Lüdemann
  • Gero Wieners
  • Bernd Hamm
  • Bernhard Gebauer
Clinical Investigation Imaging
  • 68 Downloads
Part of the following topical collections:
  1. Imaging

Abstract

Purpose

To validate a split-bolus contrast injection protocol for single-phase CBCT in terms of detectability of hypovascular liver tumors compared to digital subtraction angiography (DSA).

Materials and Methods

In this retrospective, single-center study, 20 consecutive patients with in total 77 hypovascularized tumors referred for intra-arterial therapy received a split-bolus single-phase CBCT. Two readers rated the visibility of the target tumors scheduled for embolization in CBCT and DSA compared to the pre-interventional multiphasic CT or MRI used as reference on a 3-point scoring system (1 = optimal, 3 = not visible) and catheter-associated artifacts (1 = none, 3 = extended). SNR, CNR and contrast values were derived from 37 target tumors in CBCT and MRI. Statistical analysis included the kappa test to determine interrater reliability, the Friedman’s test for the inter-modality comparison evaluating tumor visibility in DSA and CBCT as well as for quantitative assessment. Post hoc analysis included the Wilcoxon signed-rank test. p values < 0.05 were considered significant.

Results

Ninety percentage of target tumors were rated as visible in CBCT and 37.5% in DSA (p < 0.001). 70.1% of pre-interventionally detected hypovascularized tumors were depicted with CBCT and 31.2% by DSA (p < 0.001). 7.8% of known tumors were outside the FOV. Quantitative assessment showed higher image contrasts in CBCT (1.91 ± 7.01) compared to hepatobiliary-phase MRI (0.29 ± 0.14, p = 0.003) and to portal-venous (p.v.) MRI (0.31 ± 0.13, p < 0.001), but higher CNR for MRI (1.18 ± 0.80; 13.92 ± 15.82; 13.79 ± 6.65).

Conclusion

In conclusion, the split-bolus single-phase CBCT detects significantly more hypovascularized liver tumors compared to DSA performed through the proper hepatic artery with high image contrasts.

Level of Evidence

Level III, diagnostic study.

Keywords

Cone beam CT DSA Transarterial chemoembolization Hypovascularized Liver tumors 

Notes

Acknowledgements

Dr. Martin Jonczyk and Dr. Federico Collettini participate in the BIH‐Charité Clinical Scientist Program (DM.BIH-04.15) funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health.

Compliance with Ethical Standards

Conflicts of interests

MJ reports Grants from BIH Clinical Scientist and Philips Healthcare during the conduct of the study; DG reports personal fees from Bayer AG during the conduct of the study; BH reports Grants from Philips Healthcare, Bayer AG, GE, Siemens and Terumo during the conduct of the study. All other authors have nothing to disclose in relation to this article.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci Off J Jpn Soc Magn Res Med. 2007;6:43–52.Google Scholar
  2. 2.
    Fernandez R, Pappas SG, Bentrem DJ. Clinical features of metastatic hepatic malignancies. Cancer Treat Res. 2016;168:185–202.CrossRefGoogle Scholar
  3. 3.
    Schernthaner RE, Haroun RR, Duran R, et al. Improved visibility of metastatic disease in the liver during intra-arterial therapy using delayed arterial phase cone-beam CT. Cardiovasc Intervent Radiol. 2016;39:1429–37.CrossRefGoogle Scholar
  4. 4.
    Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol. 1997;7:275–80.CrossRefGoogle Scholar
  5. 5.
    Zech CJ, Korpraphong P, Huppertz A, et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg. 2014;101:613–21.CrossRefGoogle Scholar
  6. 6.
    Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: mRI. Cancer Imaging. 2007;7:2–9.CrossRefGoogle Scholar
  7. 7.
    Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol. 2017;28:1–15.CrossRefGoogle Scholar
  8. 8.
    Gaba RC, Lewandowski RJ, Hickey R, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2016;27:457–73.CrossRefGoogle Scholar
  9. 9.
    Pernot S, Artru P, Mithieux F, et al. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: a case report from the FFCD 1201 trial. Clin Res Hepatol Gastroenterol. 2015;39:e73–7.CrossRefGoogle Scholar
  10. 10.
    Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. Hepatobiliary Surg Nutr. 2017;6:7–21.CrossRefGoogle Scholar
  11. 11.
    Tognolini A, Louie JD, Hwang GL, Hofmann LV, Sze DY, Kothary N. Utility of C-arm CT in patients with hepatocellular carcinoma undergoing transhepatic arterial chemoembolization. J Vasc Interv Radiol. 2010;21:339–47.CrossRefGoogle Scholar
  12. 12.
    Wallace MJ, Murthy R, Kamat PP, et al. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol. 2007;18:1500–7.CrossRefGoogle Scholar
  13. 13.
    Kakeda S, Korogi Y, Ohnari N, et al. Usefulness of cone-beam volume CT with flat panel detectors in conjunction with catheter angiography for transcatheter arterial embolization. J Vasc Interv Radiol. 2007;18:1508–16.CrossRefGoogle Scholar
  14. 14.
    Bapst B, Lagadec M, Breguet R, Vilgrain V, Ronot M. Cone beam computed tomography (CBCT) in the field of interventional oncology of the liver. Cardiovasc Intervent Radiol. 2016;39:8–20.CrossRefGoogle Scholar
  15. 15.
    Zheng J, Li J, Cui X, Ye H, Ye L. Comparison of diagnostic sensitivity of C-arm CT, DSA and CT in detecting small HCC. Hepatogastroenterology. 2013;60:1509–12.Google Scholar
  16. 16.
    Wang Z, Chen R, Duran R, et al. Intraprocedural 3D quantification of lipiodol deposition on cone-beam CT predicts tumor response after transarterial chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38:1548–56.CrossRefGoogle Scholar
  17. 17.
    Miyayama S, Yamashiro M, Hattori Y, et al. Efficacy of cone-beam computed tomography during transcatheter arterial chemoembolization for hepatocellular carcinoma. Jpn J Radiol. 2011;29:371–7.CrossRefGoogle Scholar
  18. 18.
    Miyayama S, Yamashiro M, Hashimoto M, et al. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2013;24:501–8.CrossRefGoogle Scholar
  19. 19.
    Pung L, Ahmad M, Mueller K, et al. The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol. 2017;28:334–41.CrossRefGoogle Scholar
  20. 20.
    Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional oncology in hepatocellular carcinoma: progress through innovation. Cancer J. 2016;22:365–72.CrossRefGoogle Scholar
  21. 21.
    Schernthaner RE, Lin M, Duran R, Chapiro J, Wang Z, Geschwind J-F. Delayed-phase cone-beam CT improves detectability of intrahepatic cholangiocarcinoma during conventional transarterial chemoembolization. Cardiovasc Intervent Radiol. 2015;38:929–36.CrossRefGoogle Scholar
  22. 22.
    Kahn J, Kaul D, Boning G, et al. Quality and dose optimized CT trauma protocol–recommendation from a university level-I trauma center. Rofo. 2017;189:844–54.CrossRefGoogle Scholar
  23. 23.
    Grupp U, Schafer ML, Meyer H, et al. Reducing radiation dose in emergency CT scans while maintaining equal image quality: just a promise or reality for severely injured patients? Emerg Med Int. 2013;2013:984645.CrossRefGoogle Scholar
  24. 24.
    Brook OR, Gourtsoyianni S, Brook A, Siewert B, Kent T, Raptopoulos V. Split-bolus spectral multidetector CT of the pancreas: assessment of radiation dose and tumor conspicuity. Radiology. 2013;269:139–48.CrossRefGoogle Scholar
  25. 25.
    Scialpi M, Palumbo B, Pierotti L, et al. Detection and characterization of focal liver lesions by split-bolus multidetector-row CT: diagnostic accuracy and radiation dose in oncologic patients. Anticancer Res. 2014;34:4335–44.Google Scholar
  26. 26.
    Scialpi M, Pierotti L, Gravante S, et al. Split-bolus multidetector-row computed tomography technique for characterization of focal liver lesions in oncologic patients. Iran J Radiol. 2016;13:e20143.Google Scholar
  27. 27.
    Jonczyk M, Chapiro J, Collettini F, et al. Diagnostic accuracy of split-bolus single-phase contrast-enhanced cone-beam CT for the detection of liver tumors before transarterial chemoembolization. J Vasc Interv Radiol. 2017;28:1378–85.CrossRefGoogle Scholar
  28. 28.
    Miyayama S, Yamashiro M, Okuda M, et al. Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol. 2009;32:255–64.CrossRefGoogle Scholar
  29. 29.
    Loffroy R, Lin M, Rao P, et al. Comparing the detectability of hepatocellular carcinoma by C-arm dual-phase cone-beam computed tomography during hepatic arteriography with conventional contrast-enhanced magnetic resonance imaging. Cardiovasc Intervent Radiol. 2012;35:97–104.CrossRefGoogle Scholar
  30. 30.
    Boning G, Kahn JF, Kaul D, et al. CT follow-up in patients with neuroendocrine tumors (NETs): combined radiation and contrast dose reduction. Acta Radiol. 2018;59:517–26.  https://doi.org/10.1177/0284185117726101.CrossRefGoogle Scholar
  31. 31.
    Schernthaner RE, Chapiro J, Sahu S, et al. Feasibility of a modified cone-beam CT rotation trajectory to improve liver periphery visualization during transarterial chemoembolization. Radiology. 2015;277:833–41.CrossRefGoogle Scholar
  32. 32.
    Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015;274:320–34.CrossRefGoogle Scholar
  33. 33.
    Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind J-FH, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization. Eur Radiol. 2015;25:3255–62.CrossRefGoogle Scholar
  34. 34.
    Louie JD, Kothary N, Kuo WT, et al. Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization. J Vasc Interv Radiol. 2009;20:606–13.CrossRefGoogle Scholar
  35. 35.
    Pellerin O, Lin M, Bhagat N, Shao W, Geschwind JF. Can C-arm cone-beam CT detect a micro-embolic effect after TheraSphere radioembolization of neuroendocrine and carcinoid liver metastasis? Cancer Biother Radiopharm. 2013;28:459–65.CrossRefGoogle Scholar
  36. 36.
    Derbel H, Kobeiter H, Pizaine G, et al. Accuracy of a cone-beam CT virtual parenchymal perfusion algorithm for liver cancer targeting during intra-arterial therapy. J Vasc Interv Radiol. 2018;29(254–61):e2.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  1. 1.Department of RadiologyCharité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of HealthBerlinGermany
  2. 2.Berlin Institute of Health (BIH)BerlinGermany

Personalised recommendations